Chronic Insomnia Epidemiology Forecast 2025-2034

Chronic insomnia disorder is reported to affect 1 in 10 people, with the prevalence considerably higher in the older population. As per a review published in the Current Geriatrics Reports, up to 75% of older adults suffer from insomnia symptoms, and one-fifth of them are prescribed sleep medications. Unlike acute insomnia, chronic insomnia can severely impact daily functioning and overall well-being. Over time, it can also increase the risk of developing conditions like high blood pressure, heart disease, diabetes, and mental health disorders.

Chronic Insomnia Epidemiology Forecast Report Coverage

The “Chronic Insomnia Epidemiology Forecast Report 2034’’ offers comprehensive information on the prevalence and demographics of chronic insomnia. It projects the future incidence and prevalence rates of chronic insomnia across various populations. The study covers age, gender, and type as major determinants of the chronic insomnia-affected population. The report highlights patterns in the prevalence of chronic insomnia over time and projects future trends based on multiple variables. The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of chronic insomnia in the 8 major markets, namely, the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of chronic insomnia in the 8 major markets.

Regions Covered

• The United States
• EU-4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan
• India

Chronic Insomnia: Disease Overview

Chronic insomnia is defined as a sleep disorder where the affected patient experiences difficulty sleeping for at least three nights a week for three or more months. This long-term insomnia causes daytime sleepiness and irritability and can also affect memory and concentration. It is also reported that people suffering from chronic insomnia have a higher risk of developing diabetes, high blood pressure, substance abuse, depression, and other health problems.

Chronic Insomnia: Treatment Overview

Various studies indicate that around one-fifth of older adults are prescribed sleep medications. Common prescription drugs for chronic insomnia include benzodiazepine receptor agonists (estazolam, lorazepam, and temazepam), nonbenzodiazepine receptor agonists (eszopiclone (Lunesta) and zaleplon (Sonata)), and melatonin receptor agonists, among others. Antidepressants are sometimes prescribed to patients off-label for the treatment of this sleep disorder. Although medications are available, cognitive behavioral therapy for insomnia (CBT-I) still forms the first-line treatment for chronic insomnia as it can help the patients address negative thoughts and behaviors related to sleep.

Epidemiology

The chronic insomnia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for chronic insomnia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chronic insomnia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Around 10% of the population is affected by chronic insomnia disorder, which occurs at least 3 times a week in a span of at least 3 months, according to the American Academy of Sleep Medicine (AASM).
• A review published in the Journal of Clinical Sleep Medicine (2018) states that chronic insomnia is common among older adults, with the overall prevalence of insomnia symptoms ranging from 30% to 48% in this age group.
• A recent survey by the American Academy of Sleep Medicine in 2024 revealed that 12% of Americans are diagnosed with chronic insomnia.
• As per Chiba, Takuyo et al. (2023), the prevalence of chronic insomnia was 24.89% in Japanese emergency professionals, with stress and long working hours being the associated factors contributing to the surge in the number of such cases.

Country-wise Chronic Insomnia Epidemiology

The chronic insomnia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

Several factors such as work patterns, availability of sleep specialists, and socioeconomic variables, among others, impact the prevalence of chronic insomnia in different regions. Urbanization, stress, and rising cases of mental disorders are increasingly contributing to the growing burden of chronic insomnia. In India, one in four people (25.7% of the population) are estimated to be affected by insomnia, with a significant proportion of them developing chronic insomnia.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic insomnia based on several factors.
• Chronic Insomnia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population, the unmet needs of chronic insomnia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of chronic insomnia epidemiology in 8MM?
• What will be the total number of patients with chronic insomnia across the 8MM during the forecast period 2025-2034?
• What was the country-wise prevalence of chronic insomnia in the 8 major markets in the historical period 2018-2024?
• Which country will have the highest number of chronic insomnia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of chronic insomnia during the forecast period of 2025-2034?
• What are the currently available treatments for chronic insomnia?
• What are the disease risks, signs, symptoms, and unmet needs of chronic insomnia?

This product will be delivered within 3-5 business days.